HomeCompareSMEV vs MRK

SMEV vs MRK: Dividend Comparison 2026

SMEV yields 32258.06% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SMEV wins by $6.080919504444377e+21M in total portfolio value
10 years
SMEV
SMEV
● Live price
32258.06%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.080919504444377e+21M
Annual income
$6,044,061,792,929,915,000,000,000,000.00
Full SMEV calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — SMEV vs MRK

📍 SMEV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSMEVMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SMEV + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SMEV pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SMEV
Annual income on $10K today (after 15% tax)
$2,741,935.48/yr
After 10yr DRIP, annual income (after tax)
$5,137,452,523,990,427,000,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, SMEV beats the other by $5,137,452,523,990,427,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SMEV + MRK for your $10,000?

SMEV: 50%MRK: 50%
100% MRK50/50100% SMEV
Portfolio after 10yr
$3.0404597522221886e+21M
Annual income
$3,022,030,896,464,957,500,000,000,000.00/yr
Blended yield
99.39%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

SMEV
No analyst data
Altman Z
-9.1
Piotroski
2/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SMEV buys
0
MRK buys
0
No recent congressional trades found for SMEV or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSMEVMRK
Forward yield32258.06%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$6.080919504444377e+21M$56.8K
Annual income after 10y$6,044,061,792,929,915,000,000,000,000.00$9,798.13
Total dividends collected$6.078495418304981e+21M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SMEV vs MRK ($10,000, DRIP)

YearSMEV PortfolioSMEV Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$3,236,506$3,225,806.45$11,206$366.19+$3.23MSMEV
2$979,196,089$975,733,027.32$12,650$502.35+$979.18MSMEV
3$276,940,574,299$275,892,834,483.63$14,407$694.19+$276940.56MSMEV
4$73,220,843,454,915$72,924,517,040,414.64$16,585$967.82+$73220843.44MSMEV
5$18,097,646,590,830,880$18,019,300,288,334,120.00$19,342$1,363.89+$18097646590.81MSMEV
6$4,181,742,514,252,880,400$4,162,378,032,400,691,000.00$22,913$1,947.19+$4181742514252.86MSMEV
7$903,336,272,998,417,400,000$898,861,808,508,166,900,000.00$27,662$2,823.89+$903336272998417.38MSMEV
8$182,435,095,891,060,850,000,000$181,468,526,078,952,540,000,000.00$34,159$4,173.35+$182435095891060864.00MSMEV
9$34,446,459,359,310,920,000,000,000$34,251,253,806,707,490,000,000,000.00$43,337$6,308.80+$34446459359310917632.00MSMEV
10$6,080,919,504,444,377,000,000,000,000$6,044,061,792,929,915,000,000,000,000.00$56,776$9,798.13+$6.080919504444377e+21MSMEV

SMEV vs MRK: Complete Analysis 2026

SMEVStock

Simulated Environment Concepts, Inc. engages in the development and manufacture of medical, health, and wellness equipments in the United States and internationally. Its products include SpaCapsule, a robotic massage therapy system used for medical rehabilitation, relaxation, weight loss, slimming, cellulite management, and general wellness; and PTjetCapsule. The company also offers components, parts, accessories, and peripheral massage and health related items. Its products are used in various environments, such as corporate employee lounges, relaxation centers, gyms and health clubs, doctor's offices, hotels, tanning and beauty salons/spas, luxury accommodations, gulf clubs, ski lounges, shopping centers and malls, airports, cruise ships, luxury yachts, and homes. Simulated Environment Concepts, Inc. was founded in 1993 and is based in Miami, Florida.

Full SMEV Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this SMEV vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SMEV vs SCHDSMEV vs JEPISMEV vs OSMEV vs KOSMEV vs MAINSMEV vs JNJSMEV vs ABBVSMEV vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.